Clinical Trial Update: Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial testing allogeneic anti-CD19/BCMA CAR-T cells for patients with refractory Graves' disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Disease

Drugs mentioned

• Allogeneic anti-CD19/BCMA CAR-T

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Graves' Disease | EARLY_Phase 1 | Status: RECRUITING